Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;13(2):140-151.
doi: 10.1016/j.jalz.2016.08.003. Epub 2016 Sep 28.

Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis

Affiliations
Free article

Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis

Petroula Proitsi et al. Alzheimers Dement. 2017 Feb.
Free article

Abstract

Introduction: The aim of this study was to (1) replicate previous associations between six blood lipids and Alzheimer's disease (AD) (Proitsi et al 2015) and (2) identify novel associations between lipids, clinical AD diagnosis, disease progression and brain atrophy (left/right hippocampus/entorhinal cortex).

Methods: We performed untargeted lipidomic analysis on 148 AD and 152 elderly control plasma samples and used univariate and multivariate analysis methods.

Results: We replicated our previous lipids associations and reported novel associations between lipids molecules and all phenotypes. A combination of 24 molecules classified AD patients with >70% accuracy in a test and a validation data set, and we identified lipid signatures that predicted disease progression (R2 = 0.10, test data set) and brain atrophy (R2 ≥ 0.14, all test data sets except left entorhinal cortex). We putatively identified a number of metabolic features including cholesteryl esters/triglycerides and phosphatidylcholines.

Discussion: Blood lipids are promising AD biomarkers that may lead to new treatment strategies.

Keywords: Alzheimer's disease; Biomarkers; Brain atrophy; Classification; Dementia; Lipidomics; Machine learning; Metabolomics; Multivariate; Random forest; Rate of cognitive decline; sMRI.

PubMed Disclaimer

Publication types